OC
LUCD icon

Oppenheimer & Co’s Lucid Diagnostics LUCD Stock Holding History

Oppenheimer & Co’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.1K Hold
30,000
– – ﹤0.01% 1749
2026
Q1 		$34.5K Buy
+30,000
New +$38.2K ﹤0.01% 1673

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Oppenheimer & Co's LUCD Position: Q2 2026 in Review

Oppenheimer & Co held its Lucid Diagnostics (LUCD) position steady in Q2 2026 at 30,000 shares worth $32.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

Oppenheimer & Co first reported a position in LUCD in Q1 2026 and has held it in 2 quarters since. The position peaked at $34.5K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Oppenheimer & Co held 30,000 shares of Lucid Diagnostics worth $32.1K as of Q2 2026.
  • Oppenheimer & Co left its Lucid Diagnostics share count unchanged in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1749 holding.
  • Oppenheimer & Co first reported a position in Lucid Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • Oppenheimer & Co's Lucid Diagnostics position peaked at $34.5K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.